$NKSH

Investors in National Bankshares (NASDAQ:NKSH) have seen decent returns of 45% over the past year

National Bankshares Inc. (NASDAQ:NKSH) shareholders have experienced a 45% total shareholder return over the past year, outperforming the broader market. While the stock price itself rose 37%, dividends significantly boosted the overall return. The company also saw a substantial 101% increase in earnings per share, suggesting the market may not yet fully reflect its improved performance.

Original reporting
Yahoo Finance · Simply Wall St
Published Feb 8, 2026, 5:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Feb 8, 2026, 6:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Investors in National Bankshares (NASDAQ:NKSH) have seen decent returns of 45% over the past year — source image
Decision brief

The 30-second read

$NKSHBullishMed
01

Why it matters

The positive earnings report and shareholder returns could attract more investors, supporting a price increase. However, valuation levels and macroeconomic factors should be considered.

02

Market read

While the company demonstrates strong performance, its impact on the broader market is limited due to its regional scope and relatively small market capitalization.

03

What to watch

Potential risks include rising interest rates, regulatory changes, or economic downturns that could impact bank earnings and stock performance.

Relevance 6/10Timing: The news is recent (published on 2026-02-08), making it relevant for near-term trading decisions.

Background

National Bankshares has shown consistent growth, with recent earnings surges and shareholder returns outperforming the broader market, indicating improved financial health and investor confidence.

Company-level read

Ticker impact

$NKSHBullishMedium confidence
Context

The news highlights a significant 45% total shareholder return over the past year, driven by stock price appreciation and dividends, along with a substantial increase in earnings per share (EPS).

Expected impact

Moderate upward price movement expected in the short to medium term, contingent on continued earnings growth and market conditions.

Evidence & confidence

The company's earnings growth and shareholder returns indicate positive momentum. Nonetheless, the market may have already priced in some of this performance, and external factors could influence future movement.

Market effects

The banking and financial services sector may experience positive sentiment due to the company's strong earnings and shareholder returns.

Limited regional impact; effects are likely confined to the company's local market and sector.

Minimal global market relevance given the company's regional focus and stock size.

Counterpoint

The strong recent performance may be partly due to market over-optimism; a correction could be forthcoming if earnings growth slows or market conditions deteriorate.

Key entities

  • National Bankshares Inc.

    A regional banking institution with a focus on community banking services.

Related articles

$NKSHMed

National Bankshares, Inc. Reports Results for the Three and Six Months Ended June 30, 2026

NATIONAL BANKSHARES INC (NKSH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 nksh-ex99_1.htm NATIONAL BANKSHARES, INC. PRESS RELEASE, DATED MARCH 24, 2025 EX-99.1 EXHIBIT 99.1 FOR IMMEDIATE RELEASE CONTACTS: Lara Ramsey, President and CEO Lora M. Jones, Treasurer & CFO (540) 951-6250 lramsey@nbbank.com (540) 951-6238 ljones@nbbank.com National B

$DKNGHigh

DraftKings gets upgrade as a feared threat becomes an edge

Bank of America upgraded DraftKings (DKNG) to Buy with a $27 price target, citing prediction markets as a new opportunity. The stock rose 5.4% on Oct. 5 after a 47% decline this year. Analyst Julie Hoover sees potential revenue from prediction markets, estimating $400M in fees by 2027. Regulatory uncertainty remains a risk, but the analyst views the current stock price as an attractive entry point.

$FMCCMed

Freddie Mac (FMCC) Sells ~$428M in Non‑Performing Loans

Freddie Mac (FMCC) sold 1,968 deeply delinquent first-lien mortgages totaling $428M via auction. The four SPO pools are set to settle in December 2026, with an additional EXPO pool bid due in October 2026. This sale is part of Freddie Mac's ongoing strategy to reduce non-performing loans and seasoned assets.

$SRRKMed

Raymond James reiterates Scholar Rock stock rating on MAA resubmission

Raymond James reiterated a Strong Buy rating and $72.00 price target for Scholar Rock (SRRK) after its MAA resubmission for apitegromab in the EU. The stock trades at $41.99, down 8.6% in a week, with a $5.08B market cap. The company expects a regulatory opinion in early 2027. Analysts highlight the potential for significant non-U.S. revenue, with estimates ranging from $2.2B to $3.1B by 2035.

$BHVNMed

Raymond James reiterates Strong Buy on Biohaven stock after Japan deal

Raymond James maintained a Strong Buy rating and $30.00 price target for Biohaven Pharma (BHVN) after its licensing deal with Ono Pharma. The deal brings Biohaven $100 million in cash, extending its cash runway into 2029. The stock trades at $11.66, with a market cap of $1.79 billion. Biohaven also faces a partial clinical hold on its BHV-7000 epilepsy program. Baird reiterated an Outperform rating, while RBC downgraded to Sector Perform with a $19.00 target.

$REGNMed

REGN Maintained by RBC Capital -- Price Target Raised to $810

RBC Capital maintained a 'Sector Perform' rating for Regeneron Pharmaceuticals (REGN) but raised its price target to $810 from $737. REGN is trading at $729.42, which is 20.2% undervalued according to its GF Value™ of $914.40. The company has a GF Score™ of 87/100, indicating strong financial health and growth prospects. 10 gurus hold REGN, with 8 increasing their positions recently.